Mavodelpar
As of the edition of 20 October 2026, Mavodelpar is a small molecule: stopped in 2024; acts on PPARD.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 6, 3 stopped early
- Disease areas
- Nervous system; Bones, joints and muscles; Inherited and neonatal; Nutrition and metabolism
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Mavodelpar.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PPARD | Peroxisome proliferator-activated receptor delta | Q03181 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 2 | 0 | 2 |
| Phase 2 | 1 | 1 | 0 | 0 |
| Phase 3 | 1 | 0 | 0 | 1 |
| All trials | 6 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| High Point Pharmaceuticals | Lead sponsor of trials | 2012 to now |
| Reneo Pharma | Lead sponsor of trials | 2019 to now |